A Phase 1b Study of Ibrutinib in Combination with Obinutuzumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Researchers investigated ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia, evaluating the tolerability of 3 sequencing regimens as well as overall safety and efficacy.